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Abstract. The outcomes of treatment of physical illnesses 
are strongly affected by the presence of schizophrenia. We 
aimed to quantify the clinical course of schizophrenic breast 
cancer patients who were eligible for adjuvant chemotherapy 
to determine whether patients with this mental illness receive 
appropriate treatment for this physical illness. We searched 
the national Department of Veterans Affairs (DVA) computer 
database using computer codes for schizophrenia to identify 
patients who later developed breast cancer and were treated 
in DVA medical centers. Computer-based data were supple-
mented with chart-based clinical indicators. There were 
55 subjects who appeared to be appropriate candidates for 
adjuvant systemic therapy. A number of these candidates 
were not offered postoperative endocrine or cytotoxic chemo-
therapy, while others refused treatment or were non-compliant. 
Behaviors typical of schizophrenic subjects, including 
hostility to caregivers, often disrupt their care. Schizophrenic 
patients often have advanced-stage cancer at diagnosis, often 
delay diagnosis and are frequently hostile towards healthcare 
workers. Many of these patients refuse therapy and/or are 
non-compliant.
Introduction
Breast carcinoma is the most common type of cancer (with 
the exception of non-melanoma skin cancer) and is the second 
leading cause of cancer-related mortality in American women. 
The incidence is approximately 123 per 100,000 women in 
the United States. The age-adjusted mortality rate in the US 
is approximately 24 per 100,000 women per year. The associ-
ated lifetime risk for women is over 12%, and over 2.5 million 
women currently living have a history of breast cancer in the 
US (1). With advancements in treatment, the mortality rate has 
declined over the last few decades.
There are various effective therapies available for breast 
cancer, and breast-conserving treatment is common (2). The use 
of adjuvant systemic chemotherapy for early-stage breast cancer 
produces a 23% or greater increase in disease-free survival 
duration and a 15% or greater increase in the overall lifetime 
survival rate (3). This has led to an improved quality of life 
with generally tolerable toxicities. Accumulating evidence 
suggests that breast cancer is a heterogeneous disease (4).
The early diagnosis and optimal treatment of breast cancer 
are essential (5). Delayed detection leads to poor outcomes 
and may be due to patient factors (including late presenta-
tion or lack of appreciation of the significance of a breast 
mass), physician factors (including misdiagnosis or delay 
in consultation requests) and/or societal factors (including 
inadequate access to care or insurance-related delays). All 
of these affect patients with schizophrenia. Recent investiga-
tions have focused on the physical health status of individuals 
with schizophrenia. Breast cancer is probably more common 
in schizophrenic patients than in the population as a whole. 
In their study, Bushe et al recently reviewed this topic (6). 
However, screening for common physical illnesses, such as 
breast cancer, is substantially less among such individuals than 
in the population as a whole.
Schizophrenia is a serious mental illness characterized by 
psychotic symptoms. It is typically chronic and causes char-
acteristic abnormalities in perception, speech, behavior and 
thought. The diagnosis is based solely on clinical factors. 
Criteria for the diagnosis have been codified and published 
by the American Psychiatric Association (7) (Table I). 
Schizophrenia is believed to be the most disabling of mental 
disorders and places a large financial burden on patients, 
families and society. The incidence is low (15.2 per 100,000 
individuals per year), but lifetime prevalence is relatively high 
(7.2 per 1,000) (8,9). Approximately 1% of all populations 
worldwide studied thus far are afflicted. Since there are over 
194,000 new patients diagnosed with breast carcinoma in the 
US each year and because the prevalence of schizophrenia in 
the US is more than 1% of the population, we estimate that 
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1,000-2,000 people with schizophrenia are diagnosed with 
breast cancer each year.
Providing medical care for unrelated physical disor-
ders in schizophrenic patients presents unique challenges. 
Outcomes such as interactions between the mental illnesses 
and physical illnesses are of interest (10), but there are no 
studies pertaining to outcomes in populations of individuals 
with concurrent breast cancer and schizophrenia. Previously, 
we reported our analysis of the experience of the Department 
of Veterans Affairs (DVA) with the treatment of appendicitis 
in patients with schizophrenia (11). In this study, we aimed 
to describe the outcomes of management in a large popu-
lation-based sample of schizophrenic patients with breast 
cancer in the DVA who were offered adjuvant chemotherapy. 
Surgeons are usually dominant figures in breast cancer care. 
We therefore suggest management strategies for such patients 
based on this analysis.
Materials and methods
Materials. Approval for this study was obtained from the 
institutional review board. The Patient Treatment File (PTF), 
the national archiving system for inpatient data in the DVA 
medical system, was accessed to retrieve data of interest.
The PTF was searched to identify patients with the 
International Classification of Diseases, Ninth Revision, Clinical 
Modifications (ICD-9-CM) diagnostic codes for schizophrenia 
or schizoaffective disorder (codes 295.00-295.85) who were also 
diagnosed with breast cancer (codes 174-174.9, 198.2, 198.81, 
217, 233.0 and 611.72) during the fiscal years 1999-2005. The 
PTF identified appropriate patients based on these computer 
codes and yielded data concerning demographics, comorbid 
diseases and procedures.
To supplement the PTF data, we requested chart-based 
information from the DVA medical centers where patients 
had received their initial breast cancer treatment. These data 
included discharge summaries, progress notes, operative 
reports, medical oncology consultation summaries, psychiatry 
consultation notes and pathology reports. To obtain further 
information regarding the psychiatric history of each patient, 
we requested medical records predating admission for breast 
cancer; charts from the postoperative period were also 
obtained. Patients were classified as having received some 
type of mastectomy, lumpectomy or local excision as part of 
a curative-intent strategy if the records revealed breast carci-
noma (codes 174-174.9, 198.2, 198.81, 217, 233.0 and 611.72). 
From this pool of patients we selected patients who appeared 
to be suitable candidates for adjuvant chemotherapy, according 
to the current National Comprehensive Cancer Network (12) 
and St. Gallen consensus conference standards (13).
In total, 27 (49%) Caucasian, 19 (35%) African-American, 
3 (5%) Hispanic and 6 (11%) patients of other ethnicities 
were included in this study. There were 18 males (33%) and 
37 females (67%). The mean age at the time of surgery was 
53 years (standard deviation, 11 years). Of the 44 patients for 
whom living conditions were documented, 24 (55%) were 
no longer living independently (i.e., they were living in the 
homes of family members, assisted living facilities, group 
homes, mental institutions or nursing homes), 17 (39%) were 
independent and 3 (7%) were homeless. Additionally, 10 of the 
17 (59%) schizophrenic patients living independently at the 
time of breast cancer diagnosis for whom data were available 
had been institutionalized within two years prior to their breast 
cancer treatment.
The majority of our patients (29/55 patients, 53%) 
were diagnosed with paranoid schizophrenia (7) (Table I). 
Other subtypes of schizophrenia included undifferenti-
ated (9/55 patients, 16%), residual (2/55 patients, 4%) and 
catatonic schizophrenia (1/55 patients, 2%). Patients with 
schizoaffective disorder (15/155, 27%) were also included. Of 
the 48 patients for whom the antipsychotic drug regimen was 
specified, 13 were taking a typical antipsychotic agent (such as 
thioridazine or haloperidol), 35 were taking an atypical antipsy-
chotic agent (such as risperidone or clozapine), 5 were taking 
both types of drugs and 3 were on no antipsychotic drugs. The 
two most common outpatient medications administered were 
olanzipine (an atypical agent used by 17/48 patients, 35%) 
and risperidone (an atypical agent used by 12/48 patients, 
Table I. Diagnostic criteria for schizophrenia.
Categories Details/Explanation
Characteristic symptoms Two or more symptoms during a one-month period: delusion, hallucinations, 
 disorganized speech, disorganized/catatonic behavior and negative symptoms
Social/occupational dysfunction Marked decrease since onset of disturbance in work, relationships and self-care
Duration Continuous signs for at least six months
Organic etiology exclusion Includes: substance abuse or general medical conditions (including brain lesions,
 seizures and endocrinopathies)
Schizoaffective and Episodes of major depression, manic, or mixed episodes
mood disorder exclusion
Pervasive developmental Autism or other pervasive developmental disorders with characteristic symptoms of
disorder relationship schizophrenia for >1 month is sufficient for the diagnosis of schizophrenia
All criteria are taken from the Diagnostic and Statistical Manual of Mental Disorders (7).
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25%). Of the 38 patients for whom documentation of ability to 
provide an accurate history was available, 15 patients (39%) 
were described by a physician in the record as having a poor or 
questionable ability to provide a reliable history.
Methods and statistical analysis. We used simple descriptive 
statistics to portray the demographic data, clinical course and 
patient outcomes. Subjects were excluded from further review 
according to prespecified criteria. Mention of an abnormal 
thought or behavior in the medical record was accepted as 
evidence that it was observed by a caregiver. Lack of mention 
of an abnormal thought or behavior was accepted as evidence 
that it was not observed. Bivariate analyses were performed 
to determine the differences between schizophrenic patients 
with breast cancer and the general population using T-tests 
for continuous variables and Chi-square tests for categorical 
variables.
Results
Patient criteria. During the time period studied, 126 patients 
from 41 different VA facilities were identified by ICD-9-CM 
codes as having been diagnosed with schizophrenia and subse-
quently with breast cancer. We received data on 122 patients 
(97%); 67 patients were excluded following the chart review 
as they did not have schizophrenia, did not have breast cancer, 
had a history of breast cancer predating the diagnosis of schizo-
phrenia, did not have initial breast cancer treatment during the 
fiscal years 1999-2005, or had been deemed unsuitable for 
adjuvant chemotherapy due to comorbid conditions other than 
schizophrenia. The 55 remaining patients all had schizophrenia, 
later developed breast cancer that appeared to be curable, and 
were offered curative-intent treatment. All 55 patients appeared 
to be candidates for adjuvant chemotherapy. They were deemed 
evaluable and form the basis for this report.
Patient characteristics and behaviors. Our patient population 
comprised various ethnicities. Additionally, of the 44 patients 
whose living conditions were recorded, over half were not 
independent. Patients included were diagnosed with either 
paranoid or other subtypes of schizophrenia. 
Many patients exhibited behaviors characteristic of schizo-
phrenia during chemotherapy sessions and surgery (Table II). 
Classic evidence of disordered thought was often noted 
(Table III). Details concerning hallucinations and delusions 
were not recorded consistently; certain hospitals had recorded 
them in detail and others appeared to have recorded only the 
most notable incidents. For example, 5 of the 55 (9%) had homi-
cidal ideation documented in the medical record; 17/55 (31%) 
had documented suicidal ideation; and 12/55 patients (22%) 
had previously attempted suicide. Ten of the 55 patients (18%) 
had verbally abused ≥1 healthcare worker during ≥1 hospital 
admission and 7 (13%) patients had physically assaulted ≥1 
caregiver during ≥1 hospital admission.
Fourteen of the 35 (40%) patients for whom staging data 
were available had TNM stages III-IV; at least 5 of these 14 
(38%) patients had ignored obvious signs of breast cancer 
(mass and/or ulceration noted by patient) for six months to 
nine years; while 4 (29%) other patients with biopsy-proven 
cancer had delayed treatment for >3 months. In the 25 patients 
for whom the tumor size was recorded, 17 (68%) were >2 cm 
(mean 5.8 cm).
Among the 55 patients who appeared to be candidates for 
adjuvant cytotoxic therapy, there were 46 for whom adequate 
data on this option were available; only 39/46 (85%) were 
offered postoperative cytotoxic chemotherapy; 12 of these 
39 (31%) patients refused or were non-compliant. Among 
the 55 patients who appeared to be candidates for adjuvant 
Table II. Patient behaviors characteristic of schizophrenia 
observed in our subjects (n=55).
 n %
Unwarranted disruptive behavior 7 13
Unwarranted removal of intravenous 1 2
catheter by patient
Failure to follow activity restrictions 2 4
Requirement for restraints 1 2
Self-mutilation 1 2
Unwarranted refusal to eat 2 4
Other adverse behaviorsa 6 11
Mention of the behavior in the medical record was accepted as 
evidence that the behavior occurred and was significant enough in 
the opinion of a caregiver to warrant mention. Lack of mention of 
the behavior was taken as evidence that the behavior did not occur. 
aAttacking health care workers (with fists), throwing objects at health 
care workers, confusion about instructions from physicians leading to 
inability to appear for scheduled appointments.




Lack of insight 17 31
Auditory hallucinations 27 49
Visual hallucinations 17 31
Non-auditory/non-visual hallucinations 4 7
Delusions 26 47
Paranoia 36 65
Abnormal affect 25 45
Suspiciousness 20 36
Ideas of reference 14 25
Looseness of associations 9 16
Thought blockinga 7 13
aThought blocking (self-interruption of speech before completion) 
reflects disordered thought. Mention of the disordered thought in the 
medical record was accepted as evidence that it had been observed 
and was significant enough in the opinion of the caregiver to war-
rant mention. Lack of mention of the abnormal thought was taken as 
evidence that it was not observed.
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endocrine therapy, there were 38 for whom adequate data on 
this option were available. Only 25/38 (66%) were offered post-
operative endocrine therapy and 8 of these 25 (32%) patients 
refused or were non-compliant. Refusal to take antipsychotic 
medication was noted in the medical record of 25 of our 55 
(45%) patients, but no statistically significant correlation was 
observed between refusal to take antipsychotic medications and 
refusal to accept adjuvant cytotoxic or endocrine chemotherapy 
(Chi-square analysis). However, suicidal ideation, homicidal 
ideation and a history of assaulting health care workers were 
statistically significantly correlated with non-compliance with 
adjuvant chemotherapy (p<0.05). History of substance abuse 
was statistically significantly correlated with non-compliance 
with endocrine therapy (p<0.05).
Discussion
Schizophrenia is a chronic, debilitating illness of unclear 
etiology. The phenotype is diverse, complex and often fright-
ening to the afflicted as well as their caregivers. Modern 
genetic studies indicate that mutations in genes controlling 
neurodevelopmental sequences are etiologic factors (14-18). 
Environmental factors are also likely to be involved (16,17). 
The anatomical, physiological and biochemical mechanisms 
suggested by genetic data are penetrant in neural structures, 
conform to what is known about the pathophysiology of 
schizophrenia derived from non-genetic investigations, and 
are concordant with the effects of these candidate genes (15). 
Schizophrenia is estimated to account for 1.1% of the 
disability-adjusted life-years worldwide (8). The economic 
burden of schizophrenia is estimated to be $30-40 billion in the 
United States annually (19). It imposes a large burden on the 
affected individual, family members and society. Individuals 
with schizophrenia suffer appalling abuse throughout the 
world when under care for a physical illness such as breast 
cancer (20). Recent reports have documented widespread 
‘neglect, abandonment, indignity, cruel and inhuman treat-
ment, and punishment’ of schizophrenic subjects in spite of 
relevant international law, recommendations from interna-
tional organizations and statements from various commissions, 
professional groups and government agencies (21).
Schizophrenia is fundamentally a psychotic disorder that 
interferes with the understanding of disease processes and leads 
to non-compliance with treatments. The majority of patients 
have a paranoid component to their illness that further hinders 
compliance with care. Decreased perception of pain and/or an 
altered expression of the emotional response to pain are well 
documented (22). Even in wealthy countries, those with major 
mental illnesses have a mean life expectancy approximately 
25 years shorter than the population as a whole. Suicide, homi-
cide and similar causes account for approximately 40% of the 
increased mortality rate although medical illnesses, including 
myocardial infarction, cancer and infectious disease are also 
estimated to play a role in this increased rate. Currently, avail-
able antipsychotic drugs reduce the mortality rate; however, 
patients must ingest them to achieve this outcome (23). The 
mortality rate due to breast cancer in schizophrenic patients is 
significantly higher than that in the general population, as is 
true for most types of cancer (24). The dimensions of this effect 
in many common medical conditions have not been quantified. 
Thus, there is limited awareness of strategies to provide good 
clinical care for common physical disorders in these patients.
In 2006, there were an estimated 39.5 million hospitali-
zations in the US, according to the Agency for Healthcare 
Research and Quality (25). Approximately 1.4 million of 
these hospitalizations were due to mental illness; 7.1 million 
involved individuals with a mental illness in addition to the 
physical problem which was the primary reason for hospitali-
zation. Schizophrenia and other psychoses without physical 
illness accounted for 381,000 hospital admissions. The cost 
of treating mental illnesses in the US was estimated to be 
$58 billion/year in 2006, making it one of the most costly 
conditions (26).
A recent review of schizophrenia with answers to common 
clinical questions has been published (9). Such patients often 
have advanced-stage cancer at diagnosis, delay diagnosis, 
refuse treatment, fail to comply with adjuvant chemotherapy 
regimens and/or exhibit hostility to healthcare workers. 
Patients with schizophrenia have quantifiable abnormalities 
in their perception of pain and report pain differently than 
patients without schizophrenia (22). Similar abnormalities in 
other perceived sensations (including taste and smell) are also 
known. The incorrect interpretation of other symptoms and 
signs (presence of a breast mass, for example) appears to lead 
to delays in seeking medical attention, delayed diagnosis and 
suboptimal treatment.
In our subjects, certain presenting features, such as an 
abnormal screening mammogram (present in 74% of our 
patients), are similar to those in the general population of 
breast cancer patients. However, our patients had high rates of 
palpable breast mass (present in 80% of our patients), nipple 
retraction (present in 30%) and nipple discharge (present in 
11%) compared to non-schizophrenic subjects with breast 
cancer, providing further evidence that schizophrenic patients 
do not report symptoms as promptly as non-schizophrenic 
ones. Signs of advanced breast cancer at diagnosis may be 
related, in part, to the fact that many or most schizophrenic 
patients see primary care doctors much less frequently than 
they see psychiatrists, who focus on the control of the mental 
illness rather than the diagnosis of physical diseases such as 
cancer. The delay may be caused by patient factors (such as 
confused thoughts, illicit drug abuse, altered perception of the 
significance of evident breast lesions and abnormal percep-
tion of pain), physician factors (such as inattention to breast 
symptoms, misdiagnosis and delay in consultation requests) 
and/or societal factors (such as inadequate access to care or 
insurance-related delays in treatment). Although the inability 
to access healthcare is a significant reason for schizophrenic 
patients not receiving the necessary treatment, all of the 
patients included in this study were eligible for care in the 
DVA system.
The majority (85%) of our patients received some type 
of mastectomy rather than lumpectomy (15%). Mastectomy 
carries a higher risk of complications than lumpectomy plus an 
axillary procedure (27). Moreover, the procedure is contrary 
to the current trend towards breast-conservation management. 
Adverse events contributing to the markedly higher risk of 
premature mortality are known to occur during hospitaliza-
tion. In a large population-based study, Daumit et al estimated 
that schizophrenic patients have more than a two-fold higher 
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risk of several major complications during hospitalization 
compared to those without schizophrenia (28). Complications 
include nosocomial infections, decubitus ulcers, postop-
erative respiratory failure, deep venous thrombosis, sepsis and 
hemorrhage. Such complications were observed in our patients 
prior to adjuvant chemotherapy commencing and often delayed 
diagnosis and treatment. These adverse events and the difficul-
ties in receiving adjuvant systemic therapy presumably explain 
the increased mortality rate observed in schizophrenic breast 
cancer patients.
Our study revealed both a low rate of recommendation 
of adjuvant chemotherapy by physicians and a low rate of 
compliance by schizophrenic patients. There are numerous 
mechanisms that lead schizophrenic breast cancer patients to 
delay their care. For example, patients may believe that their 
doctors intend to harm them and often do not trust the health-
care system. Some of the patients in our series believed that 
‘cleansing teas’, meditation and other unorthodox therapies 
were more likely to cure them than conventional methods. 
Paranoia and delusions often led to violence directed towards 
healthcare workers, as was observed in 10/55 (18%) of our 
patients. We did not find a suitable published control group 
for our study. In the general population, use of adjuvant endo-
crine therapy as part of a curative-intent treatment plan for 
low-income breast cancer patients with medical insurance is 
notably low. Only 64% of patients reported by Kimmick et al 
had their prescriptions filled and the rate of adherence to the 
adjuvant treatment plan was 60% (29). Women older than 65 
with early-stage, high-risk breast cancer (not selected for the 
presence of schizophrenia but with medical insurance) also 
frequently do not receive adjuvant chemotherapy (30).
There are, however, methodological limitations to our 
study. Patients were identified by computer codes for diagnoses 
of schizophrenia without the means to check whether these 
patients fit the diagnostic criteria established by the American 
Psychiatric Association. Another confounding factor that may 
account for adverse outcomes of therapy for breast cancer is 
the use of antipsychotic drugs, which may cause major compli-
cations, including obesity, diabetes, myocarditis, sedation, 
agranulocytosis, anticholinergic effects, neuroleptic-induced 
movement disorders (including the life-threatening neuro-
leptic malignant syndrome) and death (31). Our study is a 
retrospective analysis of cases; thus, criteria for diagnoses 
and reporting patterns for clinical features and treatment of 
outcomes were presumably not recorded consistently among 
our patients. In this report, we accepted the mention of a 
symptom, sign or complication as evidence of its presence 
unless stated otherwise. Similarly, we accepted absence of 
the mention of a particular variable as evidence of its absence 
unless stated otherwise.
Our study also has several strengths. To the best of our 
knowledge, this is the largest series on this topic in the literature. 
The DVA dataset from which the cases were selected is large, 
with approximately 25 million registered veterans. Among 
these, approximately five million receive care in DVA medical 
centers each year. Most DVA subjects are male, unlike those 
in most other databases. A comparison of female and male 
breast cancer patients using the National Cancer Institute's 
Surveillance, Epidemiology and End Results (SEER) data has 
been published (32). Sharma et al recently reported the experi-
ence of the Imperial College Healthcare NHS Trust, a large 
British system based in London (33). Their aims and methods 
differed somewhat from ours. These authors concluded that 
schizophrenia does not affect the treatment of women with 
breast cancer. They acknowledge that their conclusions are 
not concordant with those of earlier reports. Our conclusions 
also differ from those of Sharma et al. The reasons for this 
discrepancy are speculative. The DVA system is enriched in 
schizophrenic subjects since it is a safety net source of care 
for poor veterans who are often homeless and/or unemployed. 
In general, individuals with schizophrenia, as is the case with 
individuals with other major mental illnesses, experience diffi-
culty receiving indicated medical care (34). The patients in our 
series had access to care in the DVA system, although they 
may have had difficulty navigating it. Due to this difficulty, our 
analysis is likely to have underestimated the effect of preex-
isting schizophrenia on the process of breast cancer treatment.
We strongly recommend that clinicians caring for schizo-
phrenic patients with a significant intercurrent physical illness 
such as breast cancer and known schizophrenia obtain a formal 
psychiatric evaluation of the patient. There are several reasons 
for obtaining such an evaluation. Having an independent 
expert opinion from a psychiatrist is essential in determining 
whether a patient is competent to make decisions about his/ her 
own medical care. The risk to caregivers and other patients 
managing a schizophrenic patient is a matter of practical 
concern that a psychiatrist is trained to assess. The available 
evidence on this topic has been summarized by Friedman (35). 
Violence in those with serious mental illness is a non-negligible 
hazard even if the illness appears to be well controlled. The 
hazard increases markedly when other predisposing factors 
(particularly drug abuse) are present (36). The psychiatrist also 
provides advice on the need for a minder to protect the patient 
from self-harm. Even a short lapse in taking antipsychotic 
medications markedly increases the risk of hospitalization in 
schizophrenics (37). This is due to the recurrence of symptoms 
of thought disorder. The authors believe that a psychiatrist 
should be an integral part of the care team in such patients.
Our data show that patients with breast cancer and preex-
isting schizophrenia often present with late-stage cancer and 
often do not understand their disease or the necessary treat-
ment. These patients delay or refuse adjuvant chemotherapy 
far more often than the population as a whole. They frequently 
do not cooperate well with caregivers and may be better served 
by radical surgery rather than breast-conserving treatment as 
an initial therapy.
The effect of major mental illness on the diagnosis and 
treatment of unrelated physical disease, as well as its effect 
on the outcome of treatment, is grossly under-researched and 
underreported. Further studies utilizing other data sets may 
clarify the effects of major mental illness on the diagnosis, 
treatment and course of unrelated physical disorders and 
provide guidance to clinicians caring for such patients.
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